{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:51:47Z","timestamp":1791870707283,"version":"4.3.4"},"reference-count":104,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T00:00:00Z","timestamp":1721865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Bialystok, Poland","award":["B.SUB.24.503"],"award-info":[{"award-number":["B.SUB.24.503"]}]},{"name":"Medical University of Bialystok, Poland","award":["B.SUB.24.165"],"award-info":[{"award-number":["B.SUB.24.165"]}]},{"name":"Medical University of Bialystok, Poland","award":["B.SUB.24.559"],"award-info":[{"award-number":["B.SUB.24.559"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurodegenerative diseases are a group of complex diseases characterized by a progressive loss of neurons and degeneration in different areas of the nervous system. They share similar mechanisms, such as neuroinflammation, oxidative stress, and mitochondrial injury, resulting in neuronal loss. One of the biggest challenges in diagnosing neurodegenerative diseases is their heterogeneity. Clinical symptoms are usually present in the advanced stages of the disease, thus it is essential to find optimal biomarkers that would allow early diagnosis. Due to the development of ultrasensitive methods analyzing proteins in other fluids, such as blood, huge progress has been made in the field of biomarkers for neurodegenerative diseases. The application of protein biomarker measurement has significantly influenced not only diagnosis but also prognosis, differentiation, and the development of new therapies, as it enables the recognition of early stages of disease in individuals with preclinical stages or with mild symptoms. Additionally, the introduction of biochemical markers into routine clinical practice may improve diagnosis and allow for a stratification group of people with higher risk, as well as an extension of well-being since a treatment could be started early. In this review, we focus on blood biomarkers, which could be potentially useful in the daily medical practice of selected neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/ijms25158132","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T14:31:07Z","timestamp":1721917867000},"page":"8132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical Application of Blood Biomarkers in Neurodegenerative Diseases\u2014Present and Future Perspectives"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6200-5232","authenticated-orcid":false,"given":"Daria","family":"Krawczuk","sequence":"first","affiliation":[{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bia\u0142ystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kulczy\u0144ska-Przybik","sequence":"additional","affiliation":[{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bia\u0142ystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4075-8479","authenticated-orcid":false,"given":"Barbara","family":"Mroczko","sequence":"additional","affiliation":[{"name":"Department of Neurodegeneration Diagnostics, Medical University of Bia\u0142ystok, 15-089 Bia\u0142ystok, Poland"},{"name":"Department of Biochemical Diagnostics, Medical University of Bia\u0142ystok, 15-089 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chi, H., Chang, H.Y., and Sang, T.K. (2018). Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103082"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Liu, H., and Zhang, X. (2022). Neurodegenerative Diseases. Pediatric Neuroimaging, Springer.","DOI":"10.1007\/978-981-16-7928-5"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1289\/ehp.7567","article-title":"Neurodegenerative diseases: An overview of environmental risk factors","volume":"113","author":"Brown","year":"2005","journal-title":"Environ. Health Perspect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neures.2013.10.004","article-title":"Neuroinflammation: The role and consequences","volume":"79","author":"Lyman","year":"2014","journal-title":"Neurosci. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2174\/1567205013666151116141603","article-title":"Diagnosis of Neurodegenerative Diseases: The Clinical Approach","volume":"13","author":"Caballero","year":"2016","journal-title":"Curr. Alzheimer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2047-9158-1-5","article-title":"Neuroimaging in the early diagnosis of neurodegenerative disease","volume":"1","author":"Stoessl","year":"2012","journal-title":"Transl. Neurodegener."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"a006221","DOI":"10.1101\/cshperspect.a006221","article-title":"Fluid biomarkers in Alzheimer disease","volume":"2","author":"Blennow","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/ADR-230029","article-title":"Plasma Biomarkers of Alzheimer\u2019s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice","volume":"7","author":"Pais","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: A priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_12","unstructured":"Duthey, B. (2004). Background Paper 6.11 Alzheimer Disease and Other Dementias, World Health Organization."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S1474-4422(07)70291-0","article-title":"Lifetime risk of stroke and dementia: Current concepts, and estimates from the Framingham Study","volume":"6","author":"Seshadri","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","article-title":"Prevalence of Biologically vs. Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer\u2019s Association Research Framework","volume":"76","author":"Jack","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_15","unstructured":"Jerzy, L. (2016). Choroba Alzheimera-Wybrane Zagadnienia Biologiczne i Kliniczne, Wyd Conlinuo."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Twarowski, B., and Herbet, M. (2023). Inflammatory Processes in Alzheimer\u2019s Disease-Pathomechanism, Diagnosis and Treatment: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076518"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neulet.2019.04.022","article-title":"The complexity of tau in Alzheimer\u2019s disease","volume":"705","author":"Naseri","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Monteiro, A.R., Barbosa, D.J., Remi\u00e3o, F., and Silva, R. (2023). Alzheimer\u2019s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem. Pharmacol., 211.","DOI":"10.1016\/j.bcp.2023.115522"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jalz.2012.10.014","article-title":"Course and etiology of dysexecutive MCI in a community sample","volume":"9","author":"Huey","year":"2013","journal-title":"Alzheimers Dement."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1038\/srep26801","article-title":"Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease","volume":"6","author":"Janelidze","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.expneurol.2009.07.024","article-title":"Amyloid beta peptides in plasma in early diagnosis of Alzheimer\u2019s disease: A multicenter study with multiplexing","volume":"223","author":"Lewczuk","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","article-title":"Plasma A[beta]40 and A[beta]42 and Alzheimer\u2019s disease: Relation to age, mortality, and risk","volume":"61","author":"Mayeux","year":"2003","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.neurobiolaging.2006.03.004","article-title":"Plasma levels of beta-amyloid (1\u201342) in Alzheimer\u2019s disease and mild cognitive impairment","volume":"27","author":"Pesaresi","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13195-020-00728-w","article-title":"Comparison of ELISA- and SIMOA-based quantification of plasma A\u03b2 ratios for early detection of cerebral amyloidosis","volume":"12","author":"Schaeverbeke","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Leuzy","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","article-title":"Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology","volume":"15","author":"Kac","year":"2024","journal-title":"Nat Commun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Pekny, M., Wilhelmsson, U., Stokowska, A., Tatlisumak, T., Jood, K., and Pekna, M. (2021). Neurofilament Light Chain (NfL) in Blood-A Biomarker Predicting Unfavourable Outcome in the Acute Phase and Improvement in the Late Phase after Stroke. Cells, 10.","DOI":"10.3390\/cells10061537"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gaiottino, J., Norgren, N., Dobson, R., Topping, J., Nissim, A., Malaspina, A., Bestwick, J.P., Monsch, A.U., Regeniter, A., and Lindberg, R.L. (2013). Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075091"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease","volume":"143","author":"Janelidze","year":"2020","journal-title":"Brain"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients with Alzheimer Disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/alz.12614","article-title":"Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer\u2019s disease risk: Results from a prospective cohort followed over 17 years","volume":"19","author":"Stocker","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: Pathogenesis, diagnostics, and therapeutics","volume":"14","author":"Tiwari","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/nn.4018","article-title":"Three dimensions of the amyloid hypothesis: Time, space and \u2018wingmen\u2019","volume":"18","author":"Musiek","year":"2015","journal-title":"Nat. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102290","DOI":"10.1016\/j.arr.2024.102290","article-title":"A critical appraisal of blood-based biomarkers for Alzheimer\u2019s disease","volume":"96","author":"Lista","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2012-120058","article-title":"Variability in blood-based amyloid-beta assays: The need for consensus on pre-analytical processing","volume":"30","author":"Watt","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neurobiolaging.2008.03.027","article-title":"Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer\u2019s disease in patients with mild cognitive impairment","volume":"31","author":"Hansson","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/alz.12801","article-title":"Clinical performance and robustness evaluation of plasma amyloid-\u03b242\/40 prescreening","volume":"19","author":"Rabe","year":"2023","journal-title":"Alzheimers Dement."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00018-019-03349-1","article-title":"Mechanisms of secretion and spreading of pathological tau protein","volume":"77","author":"Brunello","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40478-017-0489-6","article-title":"Atypical, non-standard functions of the microtubule associated Tau protein","volume":"5","author":"Sotiropoulos","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., and Reddy, P.H. (2022). Phosphorylated Tau in Alzheimer\u2019s Disease and Other Tauopathies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112841"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jalz.2018.08.013","article-title":"CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer\u2019s disease","volume":"15","author":"Huang","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e14022","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Janelidze","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41598-024-51334-x","article-title":"Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer\u2019s disease","volume":"14","author":"Fatima","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs. Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Schindler","year":"2024","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13195-018-0404-9","article-title":"Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease","volume":"10","author":"Lewczuk","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_62","first-page":"17590914221102065","article-title":"GFAP Alternative Splicing and the Relevance for Disease\u2014A Focus on Diffuse Gliomas","volume":"14","author":"Robe","year":"2022","journal-title":"ASN Neuro"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10072-019-03738-1","article-title":"Plasma alpha-synuclein levels in patients with Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"40","author":"Bougea","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.4103\/0028-3886.226451","article-title":"Parkinson\u2019s disease: A review","volume":"66","author":"Radhakrishnan","year":"2018","journal-title":"Neurol. India"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Du, X.Y., Xie, X.X., and Liu, R.T. (2020). The Role of \u03b1-Synuclein Oligomers in Parkinson\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228645"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00702-016-1650-2","article-title":"Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson\u2019s disease","volume":"124","author":"Ding","year":"2017","journal-title":"J. Neural Transm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","article-title":"Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism","volume":"91","author":"Jiang","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Cerri, S., Ghezzi, C., Sampieri, M., Siani, F., Avenali, M., Dornini, G., Zangaglia, R., Minafra, B., and Blandini, F. (2018). The Exosomal\/Total \u03b1-Synuclein Ratio in Plasma Is Associated with Glucocerebrosidase Activity and Correlates with Measures of Disease Severity in PD Patients. Front. Cell Neurosci., 12.","DOI":"10.3389\/fncel.2018.00125"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1093\/gerona\/glad189","article-title":"Evolution and Predictive Role of Plasma Alzheimer\u2019s Disease-related Pathological Biomarkers in Parkinson\u2019s Disease","volume":"78","author":"Lin","year":"2023","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","article-title":"Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson\u2019s disease","volume":"480","author":"Shi","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12264-016-0092-z","article-title":"Exosomes in Parkinson\u2019s disease","volume":"33","author":"Wu","year":"2017","journal-title":"Neurosci. Bull."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/mds.27001","article-title":"Tau\/\u03b1-synuclein ratio and inflammatory proteins in Parkinson\u2019s disease: An exploratory study","volume":"32","author":"Gago","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Schirinzi, T., Zenuni, H., Grillo, P., Bovenzi, R., Guerrera, G., Gargano, F., Pieri, M., Bernardini, S., Biagio Mercuri, N., and Battistini, L. (2022). Tau and Amyloid-\u03b2 Peptides in Serum of Patients with Parkinson\u2019s Disease: Correlations with CSF Levels and Clinical Parameters. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.748599"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis","volume":"93","author":"Dutta","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.autrev.2015.07.014","article-title":"Peripheral blood biomarkers in multiple sclerosis","volume":"14","author":"Pontecorvo","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_78","first-page":"S1","article-title":"Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management","volume":"52","author":"Efendi","year":"2015","journal-title":"Noro Psikiyatr. Ars."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and Treatment of Multiple Sclerosis: A Review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","article-title":"Association between Serum Neurofilament Light Chain Levels and Long-term Disease Course among Patients with Multiple Sclerosis Followed up for 12 Years","volume":"76","author":"Barro","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","article-title":"Serum Neurofilament Light Chain Levels in Patients with Presymptomatic Multiple Sclerosis","volume":"77","author":"Bjornevik","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bittner, S., Steffen, F., Uphaus, T., Muthuraman, M., Fleischer, V., Salmen, A., Luessi, F., Berthele, A., Klotz, L., and Meuth, S.G. (2020). Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 56.","DOI":"10.1016\/j.ebiom.2020.102807"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1352458517715132","article-title":"Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod","volume":"24","author":"Piehl","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_88","first-page":"212","article-title":"Serum Glial Fibrillary Acidic Protein: A Surrogate Marker of the Activity of Multiple Sclerosis","volume":"35","author":"Sharquie","year":"2020","journal-title":"Medeni. Med. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1126\/science.279.5350.514","article-title":"A structural scaffolding of intermediate filaments in health and disease","volume":"279","author":"Fuchs","year":"1998","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1212\/NXI.0000000000000599","article-title":"Blood neurofilament light chain at the doorstep of clinical application","volume":"6","author":"Leppert","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","author":"Kuhle","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"19982","DOI":"10.1038\/s41598-020-77098-8","article-title":"Serum neurofilament light chain withstands delayed freezing and repeated thawing","volume":"10","author":"Altmann","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0972-2327.179979","article-title":"Prions, prion-like prionoids, and neurodegenerative disorders","volume":"19","author":"Verma","year":"2016","journal-title":"Ann. Indian Acad. Neurol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2014.04.011","article-title":"Relation between clinical findings and progression of cerebral cortical pathology in MM1-type sporadic Creutzfeldt-Jakob disease: Proposed staging of cerebral cortical pathology","volume":"341","author":"Iwasaki","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/neup.12355","article-title":"Creutzfeldt-Jakob disease","volume":"37","author":"Iwasaki","year":"2017","journal-title":"Neuropathology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1750-3639.1995.tb00625.x","article-title":"Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases)","volume":"5","author":"Budka","year":"1995","journal-title":"Brain Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/jnnp-2020-323826","article-title":"Comparison between plasma and cerebrospinal fluid biomarkers for the early diagnosis and association with survival in prion disease","volume":"91","author":"Baiardi","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/nan.12573","article-title":"Plasma total prion protein as a potential biomarker for neurodegenerative dementia: Diagnostic accuracy in the spectrum of prion diseases","volume":"46","author":"Llorens","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/jnnp-2017-317793","article-title":"Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression","volume":"89","author":"Thompson","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13195-021-00815-6","article-title":"Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease","volume":"13","author":"Zerr","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00415-011-5960-x","article-title":"Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease","volume":"258","author":"Hamaguchi","year":"2011","journal-title":"J. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Mroczko, B., Groblewska, M., and Litman-Zawadzka, A. (2019). The Role of Protein Misfolding and Tau Oligomers (TauOs) in Alzheimer\u2019s Disease (AD). Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194661"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Kwon, E.H., Tennagels, S., Gold, R., Gerwert, K., Beyer, L., and T\u00f6nges, L. (2022). Update on CSF Biomarkers in Parkinson\u2019s Disease. Biomolecules, 12.","DOI":"10.3390\/biom12020329"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:23:29Z","timestamp":1760109809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/15\/8132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":104,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25158132"],"URL":"https:\/\/doi.org\/10.3390\/ijms25158132","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}